Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q1 2016 · 10-Q
Revenue$31.53K$31.53K−49.6% vs Q1 2015 Net Income-$455.04K-$455.04KN/M vs Q1 2015 EPS Diluted-$0.02-$0.02N/M vs Q1 2015 Gross Profit$14,719−69.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flow-$19,033N/M Margins · derivedGross margin46.7%−30.0 pt vs Q1 2015
Operating margin-1437.2%−1377.7 pt vs Q1 2015
Net margin-1443.4%−1380.9 pt vs Q1 2015
ended Mar 31, 2016 · filed Aug 12, 2016 · 134 d after period end